

IN VITRO ANTIBACTERIAL ACTIVITY OF CEFADROXIL CAPSULES CONSUMED BY PATIENTS IN THE HOSPITAL

Mahfudz^{1,2}, Suharjono^{3*)}, Isnaeni⁴, Primadi Avianto¹

¹Magister of Clinical Pharmacy Student, Faculty of Pharmacy, Universitas Airlangga,

²Pharmacy Section, Bangka Tengah District Health Office, Bangka Belitung, Indonesia,

³Department of Clinical Pharmacy, Faculty of Pharmacy, Universitas Airlangga,

⁴Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Airlangga,
Gedung Nanizar Zaman Joenoes, Universitas Airlangga
Mulyorejo, Surabaya, 60115, Indonesia

Received October 15, 2019; Accepted April 29, 2021

ABSTRACT

Clinical use of cefadroxil, particularly in Bangka Tengah Hospital, is proven beneficial to overcome mild to moderate infections which especially occur in soft tissues such as skin, upper respiratory tract, pharyngitis, tonsillitis and urinary tract. For this reason, it is necessary to procure cefadroxil to be available enough for the treatment of cases of these diseases. The cefadroxil used by the Central Bangka Hospital was obtained from several pharmaceutical industries with different prices and distributions, due to the possibility that the active raw materials and ingredients had different origins, so there was concern that the microbiological quality would be different. Drug procurement is carried out using the e-catalog or non-e-catalog method. This study aimed to examine the microbiological quality of six preparations (A, B, C, D, E, and F) in terms of their inhibitory activities against Gram-positive and Gram-negative bacteria. The bioassay was carried out by diffusion agar method using *Escherichia coli* ATCC 29522 and *Staphylococcus aureus* ATCC 29523 as the bacterial test, and nutrient agar as the test medium. The inhibitory activities were compared to cefadroxil standard for measuring the ratio potency. The results showed that all samples fulfilled USP 41 requirements with potential ratio of 90% to 120% and minimum inhibitory concentration of ≤ 8 ppm and ≤ 2 ppm against *Escherichia coli* and *Staphylococcus aureus* respectively. The potency ratios to cefadroxil standard were 95.9%, 99.1%, 100.0%, 96.7%, 96.2% and 98.2% against *Staphylococcus aureus* while the potency ratios of 95.6%, 99.3%, 103.8%, 97.1%, 95.7% and 100.4% were achieved against *Escherichia coli* for A, B, C, D, E, and F samples, respectively.

Keywords: Cefadroxil; potency ratio; *Escherichia coli*; *Staphylococcus aureus*

INTRODUCTION

Cefadroxil belongs to the first generation of cephalosporins besides cephradine, cephalixin, cefazoline, cephapirin and cephalothin. In Indonesia, the first generation of cephalosporin preparations available and included in the National Formulary are cefadroxil and cephalixin whereas only one e-catalog namely e-katalog.lkpp.go.id is included in the e-catalog system. Cefadroxil is prescribed for the treatment of mild to

moderate infections in soft tissues such as skin, upper respiratory tract, pharyngitis, tonsillitis and urinary tract with a dose of 500 to 1000 mg/day (Brayfield, 2014; Micromedex, 2018). The use of cefadroxil capsules in the first level health facilities (*FKTP-Fasilitas Kesehatan Tingkat Pertama*) is very limited (Kemenkes, 2017).

The number of planned drug requirements (*RKO-Rencana Kebutuhan Obat*) in Bangka Belitung Islands provincial health office for

*Corresponding author: Suharjono

Email: shj_ms_id@yahoo.com / suharjono@ff.uniar.ac.id

cefadroxil capsules is still high, reaching 294,804 in 2018 (Dinkes, 2018). The price of cefadroxil per 500 mg capsule in the e-catalog for government procurement and BPJS since 2018 is Rp488, which is valid from January 10th, 2018, until April 3rd, 2021 (LKPP, 2018).

The price is far different from what is written on the Decree of the Minister of Health of the Republic of Indonesia Number 094/Menkes/SK/II/2012, regarding the price of medicines for government procurement in 2012 which was Rp840. This price for the government was already lower than the Highest Retail Price (HET) in the same year. Based on the Government Regulation of the Republic of Indonesia Number 32 of 1991 (Anonymous, 1991) concerning import of raw materials, cefadroxil is one of those commodities that is allowed to be imported.

Cefadroxil price reduction of more than 41% by the Government Goods and Services Procurement Policy Agency in 2018 compared to 2012 prices forced pharmaceutical wholesalers (*PBF-Pedagang Besar Farmasi*) to reduce relevant fees, especially in shipping drugs to users. Direct procurement of drugs to the pharmaceutical industry can be done through e-purchasing systems. The industry appoints PBF to approve a purchase contract. Large price reductions triggered a concern over the quality of drugs (Dwiaji *et al.*, 2016). The microbiological activity test on six brands of cefadroxil capsules consumed by patients in Bangka Belitung Hospital is a strategic step to ensure the safety of the drug before it reaches the patient. This research is an experimental study to examine in vitro differences among the six different cefadroxil capsules purchased through e-catalogs and non-e-catalogs (LKPP, 2018; MIMS Indonesia, 2018). Significant price differences of the drugs between those obtained through e-catalog and non-e-catalog may indicate differences in quality as well, especially in their microbiological quality. Therefore, this study was conducted to ensure that there were no differences in microbiological quality between the products.

MATERIALS AND METHODS

Antibiotics

The six 500 mg cefadroxil capsule samples were obtained from both e-catalog and non-e-catalog. The e-catalog cefadroxil samples were purchased from the Pharmacy Installation Division and Central Bangka District Hospital, Bangka Belitung Province while the non-e-catalog ones were obtained from the Central Bangka Regency Hospital. Each sample was collected for as many as 100 capsules with the same batch number to compare the pharmaceutical grades of cefadroxil (PT. New Interbat), Dimethylsulfoxide.p.a (Merck).

Test bacteria

Staphylococcus aureus ATCC 25923 and *Escherichia coli* ATCC 29522 (Letter of statement No 115/301.25/XI/2018) were obtained from the Laboratory of Clinical Microbiology, Dr. Soetomo Hospital. Sodium chloride 0.9% was used for preparation of the test bacteria. Spectrophotometer Termo Fischer Scientific Type Genesys 20 was used to measure optical density (580 nm) of the test bacteria suspension to obtain 25% T (CLSI, 2015).

Preparation of test media

Mueler Hinton agar and broth (Difco) were used for antibacterial activity assays. Three grams of media powder was added with 150 mL distilled water, heated while stirring evenly, and sterilized with an autoclave at 120°C for 15 minutes. Media poured in petri dishes at 40°C to 50°C were then left solid to be used as a base layer. Seed layer media were prepared by inoculating a 5 µL 25% (258 nm) T test microbial suspension containing 10⁹ CFU and poured over the surface of the compacted media layer (ICH, 2005).

Minimum inhibitory concentration

In vitro antibacterial activity was evaluated using agar diffusion method on the Muller Hinton agar using a hole as reservoir. The minimum inhibitory concentration (MIC) was determined by a serial dilution on Muller Hinton broth media containing serial of

twofold a test solution. The MIC was measured after 18 to 22 hours of incubation at $35 \pm 1^\circ\text{C}$.

Potency ratio of antibiotics

The ratio of antibiotic potential in the sample to the cefadroxil standard was measured by a 3-3 design according to Farmakope Indonesia-III (Kemenkes, 1979). Three levels of test on samples and three levels of standard namely higher (H), medium (M), and lower (L) concentration solutions were achieved. The tests were carried out using agar diffusion method with a hole as reservoir. Statistical analysis of the data obtained was performed by one-way ANOVA from block random design.

RESULTS AND DISCUSSION

The inhibition of measurement of the sample solution and cefadroxil standard was carried out in a petri dish to obtain the same condition with negative control or DMSO used as a solvent (Figure 1). The minimum inhibitory concentration (MIC) was determined based on the smallest level that can inhibit the growth of test bacteria compared to positive control from cefadroxil standard (Table 1). Determination of the MIC was useful for setting lower concentration in determining the ratio of antibiotic potential (Table 2 and 4) to the standard. The lower concentration (L) should be higher than the MIC value.

Table 1. Average of minimum inhibition concentration of six samples against *S. aureus* and *E. coli*

Test Bacteria	Minimum Inhibitory Concentration ($\mu\text{g/mL}$)					
	A	B	C	D	E	F
<i>E. coli</i>	8	8	8	8	8	8
<i>S. aureus</i>	2	2	2	2	2	2




Figure 1. In vitro inhibitory activity of cefadroxil standard (G), samples A, B, C, D, E, F and DMSO (X) after incubation 18 to 22 hours at $35 \pm 1^\circ\text{C}$ on Muller Hinton agar media, *S. aureus* as a test bacteria (ppm= $\mu\text{g/mL}$).

Note: in the DMSO also created a table in the MIC value, so that readers can see clearly since DMSO can also provide an antibacterial effect.

Development and validation of a microbiological method for determination of cefadroxil capsules by turbidimetry using *S. aureus* as the test bacteria and brain heart infusion broth as the sulture medium in 3×3 parallel line assay design reported by De Marco and Salgado (2018) showed satisfactory results. The method was proven to be linear, selective, precise, robust and accurate based on ICH (2005) guidelines in a concentration range of 30 to 120 µg mL⁻¹. The developed turbidimetric method is a valid, simple, fast and more economical alternative methodology especially for the routine quality control of cefadroxil in its pharmaceutical dosage form (USP 41, 2018).

The values of turbidity of positive control from cefadroxil reference standard were 0.567 and 0.527 against *S. aureus* and *E. coli* respectively. The MIC values obtained in this study were 8 µg/mL and 2 µg/mL against *E.*

coli and *S. aureus* respectively. The value of MIC against *E. coli* was ≤ 8 µg/mL meaning that the bacteria were still sensitive. A value of 16 µg/mL indicates intermediate and a value of ≥ 32 means resistant (CLSI, 2015; USP 41, 2018). The bacteria used were standardized strains, so that all bacteria were sensitive to test antibiotics. Calculation of the potency ratio began with the observation of inhibition zones formed around the logging after incubation for 18 to 22 hours at 35 ± 1°C at low (L), medium (M) and high (H) concentrations for both test samples and standard solutions (3-3 design) according to Farmakope Indonesia-III (Kemenkes, 1979). Comparison of H:M must be the same as M:L. The results of the zone diameter measurements (Table 2 and Table 4) were calculated with the ANOVA random block design, showing a non-significant difference for all samples at p>0.05 (Table 3 and Table 5).

Table 2. Growth inhibitory activity against *E. coli*

Replication	Cons.	Growth Inhibition Zone Diameter (mm)						
		A	B	C	D	E	F	G
1	H	18.8±0.6	18.8±0.8	19.1±0.8	18.2±1.0	18.9±0.5	19.2±0.9	19.7±0.5
	M	13.8±0.8	15.2±0.8	14.2±1.4	14.2±1.0	13.8±1.2	15.2±1.7	15.0±1.1
	L	11.6±0.6	11.9±1.0	12.0±0.7	11.5±1.0	11.0±0.9	11.9±0.9	11.0±1.1
2	H	19.2±1.2	18.8±0.7	19.0±1.1	19.9±0.7	18.7±1.1	18.7±1.1	20.3±0.4
	M	14.0±0.8	15.2±0.8	15.5±0.8	14.1±1.0	14.1±1.6	14.7±1.6	15.1±1.0
	L	11.6±0.8	11.8±0.9	12.2±1.1	11.2±0.9	11.5±0.9	11.5±0.9	10.0±0.9
3	H	18.9±0.8	18.6±0.5	19.0±0.8	18.8±1.2	19.5±0.9	18.7±0.9	19.5±0.5
	M	14.0±0.9	15.3±0.9	15.5±0.8	14.6±1.3	14.2±0.9	14.9±1.5	14.8±0.9
	L	11.8±0.5	12.0±1.1	12.1±1.2	11.9±0.9	11.3±0.7	11.6±1.2	11.0±1.1
Total		45.0±2.6	45.9±1.5	44.9±2.7	45.3±2.2	45.3±2.8	46.9±3.0	45.5±2.5
p		>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05

H = Higher conc. (600 µg/mL), M = Medium conc. (300 µg/mL), L = Lower conc. (150 µg/mL); A, B, C, D, E, F = product codes, G = cefadroxil standard

Table 3. Recapitulation statistical analysis by one-way ANOVA against *E. coli*

Product	A	B	C	D	E	F	STD
A		0.558	0.273	0.999	1	0.842	0.633
B	0.558		0.999	0.842	0.697	0.999	1
C	0.273	0.999		0.558	0.391	0.965	0.997
D	0.999	0.842	0.558		1	0.979	0.891
E	1	0.697	0.391	1		0.925	0.766
F	0.842	0.999	0.965	0.979	0.925		1

Table 4. Growth inhibitory activity against *S. aureus*

Replicat ion	Cons.	Growth Inhibition Zone Diameter (mm)						
		A	B	C	D	E	F	G
1	H	18.9 ± 0.7	19.5 ± 0.3	19.6 ± 0.5	17.6 ± 0.7	18.8 ± 0.7	19.3 ± 1.1	18.8 ± 1.1
	M	13.6 ± 0.5	14.7 ± 0.6	14.7 ± 1.1	14.7 ± 0.3	13.7 ± 0.3	15.5 ± 1.6	14.8 ± 1.6
	L	11.2 ± 1.2	11.7 ± 1.0	12.4 ± 0.9	12.8 ± 1.3	11.5 ± 0.5	12.0 ± 1.1	10.8 ± 0.8
2	H	18.5 ± 1.1	19.1 ± 0.6	19.1 ± 1.1	18.6 ± 0.6	19.4 ± 0.8	19.2 ± 1.0	20.0 ± 0.9
	M	14.9 ± 0.2	14.6 ± 0.5	17.5 ± 0.7	14.2 ± 1.1	14.0 ± 1.2	14.9 ± 1.6	15.1 ± 1.4
	L	11.5 ± 1.0	12.0 ± 0.2	13.7 ± 1.4	12.2 ± 0.7	11.5 ± 1.0	11.8 ± 1.0	11.3 ± 1.1
3	H	18.4 ± 0.6	18.5 ± 0.8	18.9 ± 0.6	18.1 ± 1.0	18.7 ± 0.9	18.8 ± 1.3	20.3 ± 0.6
	M	13.6 ± 0.9	14.9 ± 0.4	14.0 ± 1.4	14.3 ± 1.1	13.8 ± 1.3	14.8 ± 1.6	15.2 ± 1.3
	L	11.6 ± 0.6	11.6 ± 1.2	11.8 ± 0.9	11.5 ± 1.0	11.0 ± 0.9	11.7 ± 0.7	11.0 ± 1.0
Total		43.9 ± 1.9	44.6 ± 1.4	43.9 ± 1.6	44.4 ± 1.6	44.3 ± 2.0	45.6 ± 1.7	45.8 ± 3.2
p		>0.05	>0.05	>0.05	>0.05	>0.05	>0.05	>0.05

H = Higher conc. (600 µg/mL), M = Medium conc. (300 µg/mL), L = Lower conc. (150 µg/mL) A, B, C, D, E, F = product codes, G = cefadroxil standard

Table 5. Recapitulation statistical analysis by one-way ANOVA against *S. aureus*

Product	A	B	C	D	E	F	G
A		0,489	0,002	0,985	1	0,192	0,305
B	0,489		0,328	0,927	0,546	0,998	1
C	0,002	0,328		0,024	0,002	0,677	0,517
D	0,985	0,927	0,024		0,992	0,654	0,799
E	1	0,546	0,002	0,020		0,228	0,352
F	0,192	0,998	0,677	0,654	0,228		1

Table 6. Ratio of potency between antibiotic in the six samples and cefadroxil standard against *S. aureus* and *E. coli*

Test Bacteria	Potency Ratio of Samples and Cefadroxil Standard (%)					
	A	B	C	D	E	F
<i>E. coli</i>	95.9	99.1	100.0	96.7	96.2	98.2
<i>S. aureus</i>	95.6	99.3	103.8	97.1	95.7	100.4

The inhibition of all samples against *E. coli* was the same while the inhibition against *S. aureus* for several samples showed different meanings (Table 3 and Table 5). The mean value of inhibition zone diameter against *E. coli* from sample D with the highest cefadroxil concentration (H) showed the smallest diameter of 18.2 ± 1.0 mm. The inhibition zone diameter of *E. coli* was smaller than the diameter of the inhibition

zone against *S. aureus* with the cefadroxil test solution at the same concentration. This phenomenon occurs due to differences in the wall structure of Gram-positive and Gram-negative bacteria. The structure of Gram-positive bacterial walls is single-layered and Gram-negative is multi-layered (multi) during the mechanism of action of cefadroxil through inhibition of cell wall synthesis (Grayson *et al.*, 2018). Antibiotics were

categorized as sensitive with a 30 µg well hole if it has a diameter value of ≥ 18 mm, intermediate if the diameter value is 15 to 17 mm, and resistant if it is ≤ 14 mm (CLSI, 2015).

The results of the calculation of the potential ratio compared to the standard were according to Farmakope Indonesia-III (Kemenkes, 1979). Referring to Table 6, it can be concluded that potential ratios were declared to meet USP 41 (2018) requirements which specify acceptance criteria of cefadroxil capsule potentials for not less than 90% and greater than 120%. The potential ratio compared to the cefadroxil standard (G) generated the values of 95.9% to 100.0% and 95.6% to 103.8% (Table 6) against *E. coli* and *S. aureus* respectively. The 500 mg cefadroxil capsules that were tested indicated that all samples met the standard of both potential ratio and MIC. This finding indicated that the drugs distributed at the health center or *puskesmas* and Bangka Tengah Hospital met the requirements. Drugs procured by e-purchasing are in principle safer than counterfeiting because they are carried out by procurement officers directly to the desired pharmaceutical industry. So, those who make agreements or contracts are not PBF. Drugs that have been announced on the e-purchasing system have gone through administrative selection especially related to eligibility requirements (LKPP, 2018).

Research on the potency of microbiological and chemical content of active substances of some cefadroxil capsules has never been done in Indonesia. Meanwhile, in Pakistan there has been a study comparing the microbiological potential of six cefadroxil capsules using *S. aureus* and *E. coli* germ isolates (Rahim *et al.*, 2014) and content examination by HPLC (Rahim *et al.*, 2015). Rahim *et al.* (2013) also reported that seven brands of cefadroxil monohydrate have been evaluated using set quality control test of weight variation, hardness, disintegration, dissolution and assay with the intention to judge whether

these seven brands are pharmaceutically equivalent with USP standard.

CONCLUSION

The potential ratio of the six cefadroxil 500 mg capsule brands to the cefadroxil standard meets USP 41 requirements. Minimum inhibitory concentration of all six brands of cefadroxil capsule products is the same and fulfills sensitive criteria based on CLSI guideline.

REFERENCES

- Anonim, 1991. Peraturan Pemerintah Republik Indonesia Nomor 32 Tahun 1991 Tentang Bahan Baku atau Produk Tertentu yang Dilindungi Paten Bagi Produksi Obat Di Dalam Negeri, Jakarta.
- Brayfield A., 2014. Martindale: The Complete Drug Reference. 38th Edition, Pharmaceutical Press, 1, 234-247.
- De Marco BA., Salgado HRN., 2018. Rapid Stability-indicative Turbidimetric Assay to Determine the Potency of Cefadroxil Monohydrate Capsules. *Analytical Method*. 6, 1-7.
- Dinkes, 2018. *Rencana Kebutuhan Obat Provinsi Kepulauan Bangka Belitung, Pangkalpinang*.
- Dwiaji A., Prih S., Hasbullah, Muhammad S., 2016. Evaluasi Pengadaan Obat Publik Pada JKN Berdasarkan Data e-Catalogue Tahun 2014-2015. *Jurnal Ekonomi Kesehatan Indonesia*, 1(1), 39-53.
- Grayson ML., Cosgrove SE., Crowe S., Hope W., McCarthy JS., Mills J., Mouton JW., Paterson DL., 2018. Kucers' The Use of Antibiotics: A Clinical Review Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, 7th Edition - Three Volume Set, 370-376.
- ICH, Harmonised Tripartite Guideline, 2005. Validation of analytical procedures: text and methodology-Q2 (R1), in: Proceedings of International

- Conference on Harmonisation, The Switzerland.
- Kementerian Kesehatan RI, 1979, Farmakope Indonesia III. Jakarta. Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan RI, 2012. Keputusan Menteri Kesehatan Republik Indonesia Nomor 094/Menkes/SK/II/2012 Tentang Harga Obat Untuk Pengadaan Pemerintah Tahun 2012. Jakarta.
- Kementerian Kesehatan, 2014, Farmakope Indonesia V. Jakarta. Kementerian Kesehatan Republik Indonesia.
- Kementerian Kesehatan, 2017. Formularium Nasional 2017. Jakarta. Kementerian Kesehatan Republik Indonesia
- LKPP, 2018. *Peraturan Lembaga Kebijakan Pengadaan Barang/Jasa Pemerintah Nomor 9 Tahun 2018 Tentang Pedoman Pelaksanaan Pengadaan Barang/Jasa Melalui Penyedia*. [WWW Document]. URL www.E-katalog.lkpp.go.id
- Micromedex, 2018. Cefadroxil. *Micromedex-IBM Watson Health*. [WWW Document] URL <https://www.micromedexsolutions.com/> (accessed 3.3.18).
- MIMS Indonesia, 2018. [WWW Document]. URL <https://www.mims.com.indonesia>
- Rahim N., Naqvi SBS., Iqbal E., Bashir S., Nesar S., Khaliq UA., Hasan EK., 2013. Investigation on Pharmaceutical Quality of Different Brands of Cefadroxil Monohydrate available in Karachi, Pakistan. *Indo American Journal of Pharmaceutical Research*, 3(6), 4577-4583
- Rahim N., Naqvi SBS., Bashir S., Rafiq K., Nesar S., 2014. Assessment of Different Brands of Cefadroxil for Their in Vitro Antibacterial Activity against *Staphylococcus aureus* and *Escherichia coli*. *International Journal of Pharmaceutical Science Invention*, 3(2), 1-6.
- Rahim N., Naqvi SBS., Shakeel S., Iffat W and Muhammad IN., 2015. Determination of Cefadroxil in Tablet/Capsule formulations by a Validated Reverse Phase High Performance Liquid Chromatographic method. *Pakistan Journal Pharmaceutical Science*, 28(4), 1345-1349.
- The Clinical and Laboratory Standards Institute (CLSI), 2015. *M100-S25 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement*. CLSI document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute, 25th edition.
- USP 41, 2018. United States Pharmacopeia. 41th edition. New York. The United States Pharmacopeial Convention.